serine and arginine rich splicing factor 3Genealiases: SFRS3 · SRp20
Q-omics provides the consensus-scored SRSF3 profile across patient tissues and cancer cell-line models. SRSF3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SRSF3 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, SRSF3 protein abundance shows 30,186 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, THCA, and LSCC as cancer lineages where SRSF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRSF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRSF3 survival associations across molecular data types. SRSF3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRSF3 RNA expression–survival associations across cancer types. High SRSF3 expression shows unfavorable associations in ACC, KIRP, LIHC and UVM, but favorable associations in KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SRSF3 RNA expression.
This table summarizes SRSF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SRSF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRSF3 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, COAD and STAD. The THCA box plot shows higher SRSF3 RNA expression in normal versus tumor tissue (log2 FC = −0.504, t-test p < 0.001).
This table shows molecular features associated with SRSF3 in patient tissues and cancer cell lines. In patient samples, SRSF3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SRSF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
